SynBioBeta Speaker
Jamie Justice
XPRIZE
EVP, Health
Dr. Jamie Justice is the Executive Vice President Health Domain and Executive Director of the $101M Healthspan Prize at the nonprofit XPRIZE Foundation, and (Adjunct) at Wake Forest University School of Medicine (WFUSM). Jamie completed graduate and postdoc training at University of Colorado Boulder. Jamie’s scientific work is dedicated to geroscience, an emerging field that targets biologic aging processes to improve age-related conditions, disability, and death. She was the recipient of the Jarrahi Research Scholars Fund in Geroscience Innovation, the Vincent Cristofalo Rising Star in Aging Research, the 2022 NIA Nathan W Shock Awardee, and was named 2026 'Top 10 Women in Longevity'. Dr. Justice’s leadership at XPRIZE uses a competition model to drive capital to innovation and catalyze transformative solutions to optimize health for all, advance personalized approaches, and ignite breakthroughs in biotechnology and biomedicine. She leads the $101M XPRIZE Healthpsan global competition to incentivize innovative solutions that make healthy human aging possible. Dr. Justice also leads the design of future prizes for health breakthroughs, including a new program to advance ovarian function across the lifespan, and future concepts targeting suicide prevention, organ thermal bioengineering, innovation in synthetic cells, and computing challenges to support better health outcomes for everyone.
SynBioBeta 2026 Tickets are Live
Confirmed Speakers
Sessions Featuring
Jamie
This Year
•
-
Human Health
Editing Inheritance: Is Human Germline Engineering Back?
Once viewed as reckless experimentation, germline gene editing is re-emerging as a serious scientific frontier. With base and prime editing now able to correct single-letter mutations with remarkable precision, researchers are beginning to demonstrate embryo edits that could one day eliminate devastating inherited diseases. The stakes, however, are profound: these are permanent, heritable changes passed to every future generation. This session examines the cutting edge of germline engineering—how far the science has advanced since CRISPR’s clumsy early days, what challenges remain around mosaicism and long-term safety, and where the ethical boundaries must be drawn. Should we consider germline editing only for rare, fatal conditions when no other reproductive options exist? Or is there a pathway to broader medical use under strict safeguards? Join leading scientists, ethicists, and policymakers as we debate whether rewriting inheritance is an act of compassion—or a step too far.
Get a Ticket
Featuring
Amy Dockser Marcus
The Information
Reporter
Eriona Hysolli
Manhattan Genomics
Co-founder
Embryo gene-correction CSO, Time100 Next honoree.
Jamie Justice
XPRIZE
EVP, Health
21.9
Jonathan Anomaly
Herasight
Professor & Founder
Philosopher-communicator at the frontier of polygenic embryo screening.
Chase Denecke
Bootstrap Bio
CEO
Embryo gene-editing startup CEO pushing ethical boundaries.
•
-
Human Health
Editing Inheritance: Is Human Germline Engineering Back?
Once viewed as reckless experimentation, germline gene editing is re-emerging as a serious scientific frontier. With base and prime editing now able to correct single-letter mutations with remarkable precision, researchers are beginning to demonstrate embryo edits that could one day eliminate devastating inherited diseases. The stakes, however, are profound: these are permanent, heritable changes passed to every future generation. This session examines the cutting edge of germline engineering—how far the science has advanced since CRISPR’s clumsy early days, what challenges remain around mosaicism and long-term safety, and where the ethical boundaries must be drawn. Should we consider germline editing only for rare, fatal conditions when no other reproductive options exist? Or is there a pathway to broader medical use under strict safeguards? Join leading scientists, ethicists, and policymakers as we debate whether rewriting inheritance is an act of compassion—or a step too far.
Get a Ticket
Featuring
Amy Dockser Marcus
The Information
Reporter
Eriona Hysolli
Manhattan Genomics
Co-founder
Embryo gene-correction CSO, Time100 Next honoree.
Jamie Justice
XPRIZE
EVP, Health
21.9
Jonathan Anomaly
Herasight
Professor & Founder
Philosopher-communicator at the frontier of polygenic embryo screening.
Chase Denecke
Bootstrap Bio
CEO
Embryo gene-editing startup CEO pushing ethical boundaries.
Session lineup still growing
Get a Ticket
Featuring
Speaker Coming Soon
•
-
Human Health
From Cells to Patients: Solving the Scale Mismatch in Virtual Biology
Drug discovery often measures biology at the cell level while interventions work at the tissue, organ, or whole-patient scale. This mismatch can make accurate cell-level predictions irrelevant in the clinic. This session dives into strategies to bridge that gap: multiscale modeling that nests single-cell dynamics within organ-level simulations, spatial transcriptomics that preserve context, and surrogate models that translate cell-level outputs into clinical biomarkers. Speakers will ask: how do we ensure virtual biology reflects not just what cells do in isolation, but how biology behaves in the real complexity of patients?
Get a Ticket
Featuring
Speaker Coming Soon
